Ong ES, Oh CL, Tan JC, et al
Authors Contributions The authors contributed equally to all aspects of the consensus process, both as participants in working groups framing the narrative and evidence base for using GLP-1/GIP RA agents in people with T1D and for the general discussion
Tuberous sclerosis complex and epilepsy: recent developments and future challenges
Designed specifically for GLP-1 users, GLP AI helps you track doses, manage side effects, and hit your protein goalsall in one simple app
The case was brought by the Outsourcing Facilities Association (OFA), a trade group that represents FDA-sanctioned compounding pharmacies, which said that ending the shortage was a reckless and arbitrary decision. The plaintiff also alleged that the FDA made its move to benefit special interests, raise drug prices, and deprive much of the public access to a needed medicine. Pittman did not buy these arguments, but with his ruling filed under seal, his exact reasoning for denying the injunction is unknown